Literature DB >> 22791781

Inflammatory osteoarthritis which was precipitated by Arimidex and resolved with tamoxifen.

Stella Williams1, Benedict Michael, Devesh Mewar, Edward Tunn.   

Abstract

We report the case of a 51-year-old woman who presented with an inflammatory flare of osteoarthritis of the small joints of her hands occurring in a temporal relationship with the commencement of Arimidex, prescribed to reduce systemic oestrogen levels to treat breast cancer. Following the cessation of Arimidex and the initiation of tamoxifen, a specific oestrogen receptor antagonist, this flare resolved. It has long been observed that during the menopause, as oestrogen levels decline, many women develop osteoarthritis or experience progression of the disease. However, this theory of oestrogen-dependent osteoarthritis has not been consistently demonstrated in animal models. As far as the authors are aware, this is the first case in which systemic oestrogen reduction has resulted in a severe osteoarthritis flare but targeted oestrogen receptor blockade led to a resolution of symptoms. These findings may inform the pathophysiological process underlying oestrogen-dependent osteoarthritis, although further series are needed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22791781      PMCID: PMC3030180          DOI: 10.1136/bcr.06.2010.3089

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

Review 1.  Osteoarthritis: epidemiology, risk factors, and pathophysiology.

Authors:  Susan V Garstang; Todd P Stitik
Journal:  Am J Phys Med Rehabil       Date:  2006-11       Impact factor: 2.159

Review 2.  No clear association between female hormonal aspects and osteoarthritis of the hand, hip and knee: a systematic review.

Authors:  Bianca M de Klerk; Dieuwke Schiphof; Frans P M J Groeneveld; Bart W Koes; Gerjo J V M van Osch; Joyce B J van Meurs; Sita M A Bierma-Zeinstra
Journal:  Rheumatology (Oxford)       Date:  2009-07-16       Impact factor: 7.580

3.  Estradiol protects cultured articular chondrocytes from oxygen-radical-induced damage.

Authors:  Horst Claassen; Michael Schünke; Bodo Kurz
Journal:  Cell Tissue Res       Date:  2005-01-25       Impact factor: 5.249

Review 4.  Animal models for osteoarthritis: the effect of ovariectomy and estrogen treatment - a systematic approach.

Authors:  Y H Sniekers; H Weinans; S M Bierma-Zeinstra; J P T M van Leeuwen; G J V M van Osch
Journal:  Osteoarthritis Cartilage       Date:  2008-02-15       Impact factor: 6.576

Review 5.  Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer.

Authors:  Sarah J Needleman; Jeffrey S Tobias
Journal:  Expert Rev Anticancer Ther       Date:  2008-12       Impact factor: 4.512

Review 6.  Selective estrogen receptor modulators: an update on recent clinical findings.

Authors:  Wendy Shelly; Michael W Draper; Venkatesh Krishnan; Mayme Wong; Robert B Jaffe
Journal:  Obstet Gynecol Surv       Date:  2008-03       Impact factor: 2.347

Review 7.  Pharmacology and clinical applications of selective estrogen receptor modulators.

Authors:  A Nath; R Sitruk-Ware
Journal:  Climacteric       Date:  2009-06       Impact factor: 3.005

Review 8.  Estrogens, cartilage, and osteoarthritis.

Authors:  Pascal Richette; Maïté Corvol; Thomas Bardin
Journal:  Joint Bone Spine       Date:  2003-08       Impact factor: 4.929

Review 9.  Limited evidence for a protective effect of unopposed oestrogen therapy for osteoarthritis of the hip: a systematic review.

Authors:  B M de Klerk; D Schiphof; F P M J Groeneveld; B W Koes; G J V M van Osch; J B J van Meurs; S M A Bierma-Zeinstra
Journal:  Rheumatology (Oxford)       Date:  2008-11-10       Impact factor: 7.580

Review 10.  Osteoarthritis associated with estrogen deficiency.

Authors:  Jorge A Roman-Blas; Santos Castañeda; Raquel Largo; Gabriel Herrero-Beaumont
Journal:  Arthritis Res Ther       Date:  2009-09-21       Impact factor: 5.156

View more
  2 in total

1.  Characteristics of adverse events of endocrine therapies among older patients with breast cancer.

Authors:  Naoko Honma; Masujiro Makita; Shigehira Saji; Tetuo Mikami; Hideaki Ogata; Rie Horii; Futoshi Akiyama; Takuji Iwase; Shinji Ohno
Journal:  Support Care Cancer       Date:  2019-02-07       Impact factor: 3.603

2.  CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen.

Authors:  Paul L Prather; FeAna FrancisDevaraj; Centdrika R Dates; Aleksandra K Greer; Stacie M Bratton; Benjamin M Ford; Lirit N Franks; Anna Radominska-Pandya
Journal:  Biochem Biophys Res Commun       Date:  2013-10-19       Impact factor: 3.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.